Rubedo Life Sciences co-founder Julian Klein (foreground) with CEO Marco Quarta (courtesy Rubedo Life Sciences)
April 22, 2024 08:36 AM EDTUpdated 08:55 AM
Financing

Rube­do pulls in $40M Se­ries A to ad­vance atopic der­mati­tis can­di­date tar­get­ing ag­ing cells

Katherine Lewin

News Reporter

Rube­do Life Sci­ences is fur­ther­ing its plan to treat age-re­lat­ed dis­eases by tar­get­ing senes­cent cells with a $40 mil­lion Se­ries A led by Khosla Ven­tures …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Evotec gains on Halozyme's takeover pro­pos­al

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

ALX On­col­o­gy hires Genen­tech, Mi­rati vet as CMO; Af­ter Car­mot, Heather Turn­er has three new roles on tap

Adap­ti­m­mune to 're­de­fine' it­self as a sar­co­ma biotech, cuts a third of staffers

Arc In­sti­tute pub­lish­es new AI mod­el Evo, cre­at­ing CRISPR sys­tems in a leap for syn­thet­ic bi­ol­o­gy

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times